Both in Pharmaceuticals
Niagen Bioscience vs Akebia Therapeutics
Over the past year NAGE returned −67.4% and AKBA returned −65.8%; their daily moves had a correlation of 0.22.
NAGE −67.4% AKBA −65.8%Growth of $1, one year, split-adjusted
| Metric | NAGE | AKBA |
|---|---|---|
| Price | $2.36 | $0.7258 |
| Market cap | $186.7M | $201.1M |
| Today | −1.67% | +2.46% |
| 1 month | −11.9% | −20.3% |
| 6 months | −51.0% | −49.9% |
| Year to date | −62.9% | −54.9% |
| 1 year | −68.7% | −67.2% |
| Revenue growth (YoY) | −4.3% | −21.4% |
| Gross margin | 64.8% | 78.8% |
| Net margin | 3.2% | −18.1% |
| P/E (TTM) | 11.7× | — |
| Price / sales | 1.4× | 0.9× |
| Net cash | $66.7M | $106.0M |
| Dividend yield | — | — |
| Volatility (60d) | 37.2% | 72.1% |
| Short % of float | 8.0% | 8.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).